A Radiologist’s Guide to Mammography, Ultrasound, Core Biopsy, and AI-Assisted Interpretation

A 37-year-old woman with a painless palpable breast mass demonstrates the central diagnostic dilemma of diabetic mastopathy: a benign fibro-inflammatory process that can reproduce the clinical and imaging phenotype of breast cancer.

When a Firm Breast Mass Looks Like Cancer

A 37-year-old woman undergoing a routine health examination was found to have a firm mass in the right breast.

There was no pain. No tenderness. No obvious skin change.

The clinical history, however, contained an important clue: she had long-standing type 2 diabetes and obesity. She had also given birth six months earlier and had breastfed.

Mammography showed very dense breast tissue and architectural distortion at the site corresponding to the palpable abnormality. Targeted ultrasound revealed an approximately 10-mm irregular hypoechoic mass, accompanied by another similar lesion measuring approximately 6 mm nearby.

At this point, the diagnostic problem was straightforward but uncomfortable:

Could this be breast cancer?

The answer could not be obtained simply by looking at the patient's diabetes history.

The imaging appearance was sufficiently suspicious to require appropriate evaluation, yet the clinical background raised another possibility: diabetic mastopathy, an uncommon benign fibro-inflammatory breast disorder associated particularly with long-standing diabetes.

The lesion was ultimately diagnosed by ultrasound-guided core needle biopsy and histopathologic examination as diabetic mastopathy.

This case illustrates one of the most important principles in breast imaging:

A clinical diagnosis may change the differential diagnosis, but it should not override suspicious imaging findings.

Diabetic mastopathy is important precisely because it occupies this uncomfortable diagnostic space. It can feel like cancer, look like cancer, and trigger a cancer-oriented workup—while remaining a benign disease.

Learning Objectives

After reading this article, the reader should be able to:

Recognize the typical clinical presentation of diabetic mastopathy.
Understand why diabetic mastopathy can mimic breast malignancy on mammography and ultrasound.
Correlate lymphocytic inflammation and dense fibrosis with the imaging phenotype.
Identify situations in which image-guided core needle biopsy is appropriate.
Understand why a history of diabetes should broaden, rather than prematurely narrow, the differential diagnosis.
Appreciate the potential and limitations of AI-assisted breast imaging in rare fibro-inflammatory disease.

1. What Is Diabetic Mastopathy?

Diabetic mastopathy is a rare benign fibro-inflammatory disorder of the breast associated with long-standing diabetes.

The terminology used in the literature includes:

diabetic mastopathy;
diabetic fibrous mastopathy;
sclerosing lymphocytic lobulitis;
lymphocytic mastitis.

Historically, the condition was most strongly associated with long-standing type 1 diabetes, particularly in patients receiving insulin therapy. However, type 2 diabetes does not exclude the diagnosis.

The case presented here is therefore clinically instructive: the patient had long-standing type 2 diabetes, demonstrating why diabetes type alone should not be used as an exclusion criterion.

The disease is uncommon, accounting for less than 1% of benign breast diseases in the material reviewed for this case.

Its importance is therefore not its prevalence.

Its importance is the diagnostic trap it creates.

A patient may present with a rock-hard, painless mass. Mammography may demonstrate architectural distortion. Ultrasound may demonstrate an irregular hypoechoic lesion with an indistinct margin and posterior shadowing.

These are precisely the types of findings that make a radiologist think about malignancy.

2. Anatomy Review: Why Fibrosis Changes the Imaging Appearance

The breast consists of a complex arrangement of:

lobular glandular units;
terminal duct lobular units;
ducts;
stromal connective tissue;
adipose tissue;
vascular structures;
lymphatic channels.

Diabetic mastopathy predominantly involves the stromal and lobular environment, where chronic lymphocytic inflammation and fibrosis alter the mechanical properties of the tissue.

Figure 1. Breast Anatomy and the Anatomical Basis of Diabetic Mastopathy

Schematic representation of the breast demonstrating the terminal duct lobular unit, ducts, stromal tissue, vascular structures, and surrounding adipose tissue. The figure should emphasize the relationship between lymphocytic inflammation, lobular structures, and progressive stromal fibrosis.

The anatomical framework matters because fibrosis is not simply an incidental histologic observation. It changes the physical behavior of breast tissue.

3. Pathophysiology: Why Does Diabetes Produce a Fibrotic Breast Mass?

The precise mechanism of diabetic mastopathy remains incompletely established.

The current conceptual model involves an interaction between chronic metabolic disturbance, immune-mediated inflammation, and progressive fibrosis.

The characteristic histologic findings include:

periductal lymphocytic infiltration;
perilobular lymphocytic infiltration;
perivascular lymphocytic infiltration;
dense stromal fibrosis;
keloid-like fibrosis;
epithelioid fibroblasts;
predominance of B lymphocytes.

The imaging consequence follows a logical sequence:

This explains why the disease can produce a lesion that is physically hard on examination and hypoechoic on ultrasound.

Dense fibrosis also increases acoustic attenuation and can produce posterior acoustic shadowing.

In other words, the ultrasound appearance is not arbitrary.

It is the imaging expression of the underlying tissue architecture.

Figure 2. Pathophysiology–Imaging Correlation

Conceptual pathway demonstrating how chronic diabetes-associated inflammatory and fibrotic changes can produce a firm palpable mass, architectural distortion on mammography, and an irregular hypoechoic lesion with posterior acoustic shadowing on ultrasound.

4. Epidemiology

Because diabetic mastopathy is uncommon, large epidemiologic datasets remain limited.

The typical clinical profile described in the case material includes long-standing diabetes, particularly type 1 diabetes, insulin treatment, younger or middle-aged women, and occasionally associated diabetic microvascular complications or autoimmune disease. Multiple and bilateral lesions may occur, and recurrence is recognized.

Table 1. Clinical Epidemiology of Diabetic Mastopathy

Characteristic	Clinical Interpretation
Disease frequency	Rare
Typical patient	Younger or middle-aged woman
Diabetes	Strong clinical association
Traditional association	Long-standing type 1 diabetes
Type 2 diabetes	Does not exclude the diagnosis
Insulin therapy	Frequently reported
Microvascular complications	May coexist
Autoimmune disease	May coexist
Multiplicity	Possible
Bilaterality	Possible
Recurrence	Recognized

A 2024 single-center study cited in the case material included 28 patients; 82% had type 1 diabetes, and the median interval between diabetes diagnosis and diabetic mastopathy was approximately 15 years.

The same study reported diabetic complications in 73% of patients, including retinopathy, neuropathy, and nephropathy, while 42% had associated autoimmune disease.

These numbers should be interpreted cautiously because they originate from a relatively small cohort rather than a population-based epidemiologic study.

5. Clinical Presentation

The classic presentation is deceptively simple:

A firm, painless breast mass.

That presentation creates the first diagnostic problem because a firm, painless mass is also a classic reason to investigate breast malignancy.

In this case, the lesion was palpable in the right breast at approximately the 2 o'clock position, 2–3 cm from the nipple. There was no associated pain, tenderness, or skin change.

The clinical history of recent pregnancy and lactation adds another layer of complexity.

A postpartum breast may demonstrate benign lactational changes, including entities such as galactocele or lactating adenoma. Therefore, the radiologist must integrate both the metabolic history and reproductive history.

Red Flags

A palpable breast mass requires particularly careful assessment when there is:

interval growth;
suspicious skin retraction;
nipple change;
suspicious axillary lymphadenopathy;
imaging-palpation discordance;
a new lesion at a different site in a patient previously diagnosed with diabetic mastopathy.

A history of diabetic mastopathy does not mean that every subsequent breast mass has the same diagnosis.

6. Mammography: Architectural Distortion Is Not Synonymous With Cancer

The mammographic examination demonstrated very dense breast tissue.

A radiopaque marker corresponded to the palpable area, and architectural distortion was present around the marker.

Figure 3. Mammography—Craniocaudal View

The right breast demonstrates marked mammographic density. At the site corresponding to the palpable abnormality, there is architectural distortion of the surrounding parenchymal pattern.

Diagnostic significance:
Architectural distortion is an important mammographic sign of malignancy, but it is not pathognomonic for cancer.

Severe fibrosis can produce the same structural rearrangement.

This distinction is crucial in diabetic mastopathy.

The radiologist should therefore ask two separate questions:

Is the architectural distortion suspicious?
What conditions could plausibly produce this appearance in this patient?

Diabetic mastopathy belongs in the second question.

Figure 4. Mammography—Mediolateral Oblique View

The MLO projection again demonstrates dense fibroglandular tissue and corresponding architectural alteration at the site of the palpable abnormality.

The combination of dense breast tissue and architectural distortion makes ultrasound correlation particularly important.

The case material notes that mammographic visibility can be limited in dense breasts and that diabetic mastopathy may present as asymmetric density or ill-defined opacity rather than as a discrete mammographic mass.

Imaging Pearl

A negative or nonspecific mammogram does not invalidate a clinically significant palpable mass.

This principle becomes especially important in dense breasts.

7. Targeted Ultrasound: Where the Diagnostic Problem Becomes Visible

Targeted ultrasound was particularly important in this case.

At the palpable site, ultrasound demonstrated an approximately 10-mm irregular hypoechoic mass. A second similar lesion measuring approximately 6 mm was also identified nearby.

Figure 3. Targeted Breast Ultrasound

Figure 3. Targeted ultrasound of the palpable right-breast abnormality demonstrates an irregular, hypoechoic lesion with an indistinct and irregular contour. The measured dimensions shown on the ultrasound image are approximately 1.17 cm in the longest dimension, 0.61 cm in the transverse dimension, and 0.38 cm in the anteroposterior dimension. The lesion demonstrates a markedly hypoechoic appearance with posterior acoustic shadowing. A similar adjacent hypoechoic lesion is also identified.

The dominant lesion demonstrates several features that warrant careful evaluation:

Irregular morphology
Hypoechoic echogenicity
Approximately 1.17 cm in maximum measured dimension
Indistinct/irregular margins
Marked posterior acoustic shadowing
A similar smaller adjacent lesion

Typical Ultrasound Phenotype

The case material identifies the following recurring pattern:

In one cited 2019 case series, irregular morphology was reported in 81.3%, indistinct margins in 100%, marked hypoechogenicity in 87.5%, and posterior acoustic shadowing in 62.5%.

The critical point is not the percentages themselves.

It is the overlap.

These ultrasound features are also characteristic warning signs for breast malignancy.

Therefore:

Diabetic mastopathy should be suspected clinically, but suspicious imaging still requires appropriate tissue diagnosis.

8. Color Doppler: Useful, but Not a Diagnostic Escape Route

Color Doppler provides an additional layer of information when evaluating a suspicious breast lesion, particularly when conventional grayscale ultrasound findings are indeterminate.

In this case, color Doppler demonstrates vascular signals predominantly around the lesion and within the adjacent breast tissue. However, there is no conspicuous internal hypervascularity on the displayed image.

This finding is supportive only in a limited sense.

Figure 4. Color Doppler Evaluation of the Breast Lesion

Figure 4. Color Doppler ultrasound demonstrates several vascular signals around the irregular hypoechoic breast lesion and within the adjacent breast tissue. No striking internal hypervascularity is demonstrated on this image. The Doppler findings are therefore complementary rather than independently diagnostic.

The principal observation on this Doppler examination is the distribution of vascular signals relative to the lesion.

Color flow is demonstrated adjacent to and around the hypoechoic lesion, while there is no prominent pattern of diffuse internal hypervascularity.

This finding should be interpreted cautiously.

Low vascularity does not establish benignity.

Likewise, the presence of vascularity does not automatically establish malignancy.

Doppler vascularity can be influenced by several factors, including lesion composition, vascular architecture, Doppler sensitivity, flow velocity, scale settings, and the technical characteristics of the examination. Consequently, the absence of conspicuous internal flow should not be used as a reason to dismiss an otherwise suspicious mass.

In this case, the Doppler examination adds contextual information, but it does not resolve the fundamental diagnostic question.

The more important sonographic assessment remains the morphology of the lesion on grayscale ultrasound.

For a palpable breast mass, the radiologist should integrate:

Color Doppler should therefore function as an adjunct to lesion characterization, rather than a diagnostic escape route from an otherwise suspicious grayscale appearance.

Doppler vascularity should modify, not replace, morphological assessment.

A lesion without striking internal vascularity can still be clinically important, while vascular signals within or around a lesion do not by themselves establish malignancy.

In a patient with suspected diabetic mastopathy, this distinction is particularly important. Fibro-inflammatory tissue can produce a complex imaging phenotype that overlaps with malignancy. The final interpretation should therefore integrate clinical history, mammographic findings, grayscale ultrasound morphology, Doppler characteristics, and—when imaging remains suspicious—histopathologic assessment.

9. What About CT and MRI?

CT is not a first-line test for evaluating a palpable breast mass.

Its role is generally secondary—for example, when breast tissue is incidentally included on a CT examination performed for another clinical reason or when another systemic process is being investigated.

MRI can be useful as a problem-solving modality in selected circumstances.

However, MRI does not automatically solve the diagnostic problem.

Diabetic mastopathy can demonstrate enhancement patterns that overlap with malignancy. Consequently, MRI should not be treated as a substitute for tissue diagnosis when the clinical and imaging findings remain suspicious or discordant.

This is an important example of a broader principle in medical imaging:

A more sophisticated modality does not necessarily produce a more definitive diagnosis.

10. BI-RADS: Diabetes Should Not Automatically Lower Suspicion

The lesion in this case was irregular and hypoechoic on ultrasound, while architectural distortion was present on mammography.

The appropriate response is not:

"The patient has diabetes, therefore the lesion is benign."

The appropriate response is:

"Diabetic mastopathy is an important differential diagnosis, but the imaging phenotype overlaps with malignancy and requires appropriate diagnostic evaluation."

The case material emphasizes that diabetic mastopathy should not automatically be assigned a benign BI-RADS category simply because the patient has diabetes.

The clinical history modifies the pretest probability and differential diagnosis.

It does not erase suspicious imaging features.

11. Why Core Needle Biopsy Matters

The decisive diagnostic step in this case was ultrasound-guided core needle biopsy.

This is important because diabetic mastopathy may be difficult to diagnose using cytology alone.

Dense fibrosis can limit the diagnostic yield of fine-needle aspiration.

A core biopsy provides a larger tissue sample and allows the pathologist to evaluate the characteristic fibro-inflammatory architecture.

The case material identifies image-guided core needle biopsy as an important diagnostic tool and notes that it can help reduce the need for unnecessary surgical excision.

Imaging-Pathology Concordance

The diagnostic endpoint is not simply:

"Biopsy says diabetic mastopathy."

The stronger endpoint is:

Imaging + clinical findings + pathology = concordant diagnosis

If the pathology appears benign but does not adequately explain a highly suspicious imaging abnormality, the diagnostic process must continue.

That is the meaning of radiologic-pathologic concordance.

12. Pathology: The Tissue Explains the Image

Histologically, diabetic mastopathy is characterized by a distinctive fibro-inflammatory pattern.

Important findings include:

Lymphocytic Lobulitis

Lymphocytes accumulate around lobular structures.

Lymphocytic Ductitis

Inflammatory lymphocytic infiltration can surround ducts.

Perivascular Lymphocytic Infiltration

Lymphocytes may also accumulate around vessels.

Dense Fibrosis

Dense collagenous fibrosis is central to the disease phenotype.

It provides a direct pathological explanation for the firm consistency of the mass and the acoustic shadowing that can appear on ultrasound.

B-Cell Predominance

B-cell predominance has been described as an important immunophenotypic feature.

The imaging-pathology relationship can therefore be summarized as:

This is why diabetic mastopathy is better conceptualized as a pseudotumoral fibro-inflammatory process than simply as a "breast lump associated with diabetes."

13. Differential Diagnosis

The most important differential diagnosis is breast carcinoma.

Other possibilities depend on the clinical context and include:

fibroadenoma;
lactating adenoma;
galactocele;
fat necrosis;
chronic mastitis;
granulomatous mastitis;
radial scar;
other fibrosing breast disorders.

The postpartum history in this patient makes lactational entities particularly relevant.

Table 2. Imaging Differential Diagnosis

Diagnosis	Imaging Pattern	Pathology	Key Differentiating Point
Diabetic mastopathy	Irregular hypoechoic mass, possible shadowing, architectural distortion	Lymphocytic inflammation + dense fibrosis	Long-standing diabetes; imaging-pathology correlation required
Breast carcinoma	Irregular mass, distortion, suspicious margins	Malignant epithelial proliferation	Must be excluded when imaging is suspicious
Fibroadenoma	Usually oval, circumscribed, parallel	Fibroepithelial lesion	Generally more circumscribed
Lactating adenoma	Variable solid mass during lactation	Lactational change	Strong temporal relationship to lactation
Galactocele	Usually cystic/fat-fluid characteristics	Milk-containing cyst	Lactational context
Fat necrosis	Variable, sometimes highly suspicious	Necrotic adipose tissue	History of trauma/surgery may help
Granulomatous mastitis	Variable inflammatory mass	Granulomatous inflammation	Clinical inflammatory context
Radial scar	Architectural distortion	Complex sclerosing lesion	Histologic evaluation often necessary

No single imaging feature reliably separates diabetic mastopathy from carcinoma in every patient.

That is why the diagnostic strategy must remain integrated.

14. Treatment: Does Every Patient Need Surgery?

No.

Diabetic mastopathy is a benign condition.

When pathology is definitive, imaging-pathology concordance is established, and the patient is asymptomatic, conservative management with clinical and imaging follow-up can be appropriate.

Surgical management may be considered when there is:

substantial pain;
rapid enlargement;
persistent symptoms;
imaging-pathology discordance;
persistent diagnostic uncertainty;
inability to adequately exclude malignancy.

The purpose of surgery in these circumstances is diagnostic or symptomatic—not treatment of a malignant disease.

This distinction matters.

Diabetic mastopathy itself is not a cancer that metastasizes because surgery was delayed. The greater clinical danger may be unnecessary surgery caused by failure to recognize the benign fibro-inflammatory diagnosis.

15. Prognosis and Recurrence

The prognosis of diabetic mastopathy is generally favorable because it is a benign disorder.

Recurrence, however, is an important clinical issue.

A 2024 study cited in the case material reported recurrence in approximately 32% of surgically treated patients, predominantly within the first year after surgery.

This creates another diagnostic trap.

A recurrent lesion may represent recurrent diabetic mastopathy.

But a new lesion cannot automatically be labeled recurrent diabetic mastopathy simply because the patient has a previous diagnosis.

Every new palpable or imaging-detected lesion deserves appropriate reassessment.

The available evidence does not establish diabetic mastopathy itself as a clearly demonstrated independent breast-cancer risk factor, but malignancy still has to be excluded whenever clinically or radiologically indicated.

16. The Diagnostic Pathway That Matters

For this case, the practical workflow can be summarized as:

The key is not to make the pathway longer than necessary.

It is to make it diagnostically coherent.

17. Why Ultrasound Matters So Much in Dense Breasts

This case provides a particularly useful lesson in dense-breast imaging.

Mammography showed substantial breast density, limiting conspicuity of the underlying lesion. Ultrasound directly demonstrated the palpable abnormality and its adjacent counterpart.

Therefore:

In a patient with a palpable abnormality and dense breasts, targeted ultrasound can become the decisive imaging test for lesion localization and characterization—even when it cannot determine benignity by itself.

The purpose of ultrasound is not simply to "find the lump."

It allows the radiologist to establish:

whether the palpable area corresponds to a structural abnormality;
whether there is one lesion or several;
whether the lesion is solid or cystic;
whether its morphology is suspicious;
whether image-guided biopsy is feasible.

18. What Should the Radiologist Actually Say?

A clinically useful impression should avoid both extremes.

Too Reassuring

"Findings are probably diabetic mastopathy because the patient has diabetes."

This risks underdiagnosis of cancer.

Too Aggressive

"Highly suspicious breast mass requiring immediate surgical excision."

This may result in unnecessary surgery when a core biopsy could establish a benign diagnosis.

Better Clinical Reasoning

A more appropriate approach is:

Irregular hypoechoic palpable lesion with associated architectural distortion. Given the suspicious imaging morphology, tissue diagnosis is recommended. Diabetic mastopathy is included in the differential diagnosis in view of the patient's long-standing diabetes; however, imaging findings overlap with malignancy and cannot establish benignity.

This language preserves both diagnostic safety and clinical nuance.

19. Radiologist Reading Report

Findings

The right breast demonstrates marked fibroglandular density. At the site of the palpable abnormality, mammography demonstrates architectural distortion.

Targeted ultrasound demonstrates an approximately 10-mm irregular hypoechoic mass at the 2 o'clock position, approximately 3 cm from the nipple, with an adjacent similar approximately 6-mm lesion. The lesions demonstrate suspicious morphology, with indistinct margins. No definitive hypervascularity is demonstrated on color Doppler.

Impression

Irregular palpable right-breast masses with associated architectural distortion. The imaging appearance is suspicious and overlaps with malignancy. Diabetic mastopathy is included in the differential diagnosis given the patient's long-standing diabetes; however, imaging findings are not sufficiently specific for benign diagnosis. Ultrasound-guided core needle biopsy is recommended, followed by assessment of imaging-pathology concordance.

20. Artificial Intelligence Perspective

Diabetic mastopathy represents an interesting stress test for clinical AI.

A conventional breast AI system is trained to identify imaging patterns associated with malignancy.

But diabetic mastopathy can generate some of the same visual signals.

This creates an important distinction:

Pattern recognition is not the same as disease understanding.

What AI Might Detect

An AI model could potentially identify:

irregular shape;
margin abnormality;
hypoechogenicity;
architectural distortion;
lesion multiplicity;
tissue asymmetry;
suspicious spatial relationships.

What AI May Not Understand

A model may not reliably understand that:

represents a coherent benign disease process.

The challenge becomes even greater in rare diseases because training datasets tend to contain far fewer examples than common breast malignancies.

21. Radiomics

Radiomics could theoretically quantify features such as:

texture;
heterogeneity;
shape;
intensity;
spatial relationships;
enhancement characteristics.

However, diabetic mastopathy is rare, and any radiomics application would require adequate datasets, external validation, and careful assessment of generalizability.

A radiomic signature developed from a small single-center cohort should not automatically be treated as a clinically validated diagnostic biomarker.

22. Foundation Models and Vision-Language Models

The emergence of medical imaging foundation models and vision-language models creates a different possibility.

Instead of asking only:

"Does this image look malignant?"

a multimodal system could potentially integrate:

Image + age + diabetes duration + pregnancy/lactation history + physical findings + previous imaging + pathology

and generate a more clinically contextualized differential diagnosis.

This is potentially valuable for rare diseases.

But it introduces a new risk:

a model that knows the disease exists may become overconfident in recognizing it.

Therefore, AI-generated suggestions must remain subordinate to:

image quality;
radiologist interpretation;
appropriate BI-RADS assessment;
tissue diagnosis;
pathology;
clinical-pathologic concordance.

23. Enterprise Clinical AI Workflow

In a mature clinical environment, AI should not operate as an isolated application.

A potential architecture is:

The goal is not simply to install an AI algorithm.

The goal is to integrate the algorithm into a controlled clinical workflow.

For rare breast disease, that could mean:

lesion detection;
automated measurement;
comparison with prior examinations;
suspicious-feature highlighting;
report assistance;
structured differential suggestions;
decision-support prompts.

But the system should not silently convert an AI probability into a clinical diagnosis.

24. AI Failure Modes

Several failure modes deserve attention.

False Positive Escalation

If AI interprets fibrosis as malignancy, it may increase unnecessary recalls or biopsies.

False Negative Reassurance

If the model has poor representation of rare disease phenotypes, it may underestimate a suspicious lesion.

Dataset Bias

A model trained predominantly on common breast cancers may not generalize to rare fibro-inflammatory disease.

Context Failure

The model may ignore diabetes duration or recent lactation.

Automation Bias

Radiologists may give excessive weight to AI output.

Model Drift

Changes in ultrasound equipment, mammography systems, patient populations, or acquisition protocols can alter AI performance.

Therefore, clinical AI should be continuously monitored rather than validated once and forgotten.

25. Future of Precision Imaging

Diabetic mastopathy illustrates why future precision medicine will increasingly depend on multimodal integration.

Potential technologies include:

Radiogenomics

Linking imaging phenotypes with molecular characteristics.

Federated Learning

Allowing institutions to contribute to model development without centralizing all patient data.

Synthetic Data

Potentially expanding representation of rare imaging phenotypes, although synthetic data must be rigorously validated.

Digital Twins

Long-term patient-level modeling could eventually integrate metabolic history, imaging, pathology, and longitudinal outcomes.

Multimodal AI

The most clinically useful systems may ultimately combine:

Imaging + EHR + pathology + laboratory data + longitudinal history

rather than treating each modality independently.

These remain evolving technologies rather than established standards for diabetic mastopathy.

26. Clinical Pearls

A painless firm breast mass in a patient with long-standing diabetes should raise the possibility of diabetic mastopathy.
Type 2 diabetes does not exclude diabetic mastopathy.
Architectural distortion is suspicious but not synonymous with malignancy.
Dense breast tissue can limit mammographic sensitivity.
Targeted ultrasound is particularly important when a palpable lesion is present in dense breasts.
Irregular hypoechoic morphology can occur in diabetic mastopathy and breast cancer.
Posterior acoustic shadowing may reflect dense fibrosis.
Multiplicity or bilaterality can provide a diagnostic clue but cannot establish benignity.
Color Doppler should be regarded as complementary rather than decisive.
MRI does not eliminate the need for biopsy when imaging-pathology uncertainty remains.
Core needle biopsy is particularly valuable because fibrosis can limit cytologic sampling.
Radiologic-pathologic concordance is essential.
Pathologically confirmed asymptomatic diabetic mastopathy does not automatically require surgery.
Recurrence can occur, particularly after surgical treatment.
A new breast mass in a patient with previous diabetic mastopathy should be reassessed rather than automatically labeled recurrent disease.

27. Quiz

Question 1

A 37-year-old woman with long-standing type 2 diabetes has a painless palpable breast mass. Mammography shows architectural distortion, and ultrasound demonstrates an irregular hypoechoic mass. What is the most appropriate next step?

① Annual screening mammography
② Empirical antibiotic treatment
③ Ultrasound-guided core needle biopsy
④ CT of the chest
⑤ Immediate wide surgical excision

Answer: ③

Explanation:
The imaging findings overlap with malignancy. Diabetes raises diabetic mastopathy in the differential but does not justify downgrading suspicious imaging. Core needle biopsy provides an appropriate route to tissue diagnosis.

Question 2

Which histopathologic pattern is most characteristic of diabetic mastopathy?

① Extensive fat necrosis with dystrophic calcification
② Predominantly granulomatous inflammation
③ B-cell-predominant lymphocytic infiltration with dense fibrosis
④ Invasive malignant epithelial proliferation
⑤ Mucin-producing malignant cells

Answer: ③

Explanation:
The characteristic pattern includes lymphocytic lobulitis, lymphocytic ductitis, perivascular lymphocytic infiltration, and dense fibrosis, with B-cell predominance described in the pathology.

Question 3

Which statement regarding management is most appropriate?

① Diabetic mastopathy is a premalignant lesion requiring wide excision.
② MRI findings can reliably eliminate the need for biopsy.
③ Recurrence is sufficiently rare that follow-up is unnecessary.
④ A pathologically confirmed asymptomatic lesion may be managed conservatively.
⑤ Type 2 diabetes excludes the diagnosis.

Answer: ④

Explanation:
Diabetic mastopathy is benign. When the diagnosis is secure, imaging-pathology concordance is established, and symptoms are absent, surveillance may be appropriate.

28. Frequently Asked Questions

1. What is diabetic mastopathy?

Diabetic mastopathy is a rare benign fibro-inflammatory breast disorder associated with long-standing diabetes and characterized histologically by lymphocytic inflammation and dense fibrosis.

2. Can diabetic mastopathy look like breast cancer?

Yes. It can produce a firm palpable mass, architectural distortion, irregular hypoechoic morphology, indistinct margins, and posterior acoustic shadowing.

3. Can patients with type 2 diabetes develop diabetic mastopathy?

Yes. Although historically associated more strongly with long-standing type 1 diabetes, type 2 diabetes does not exclude the diagnosis.

4. What does diabetic mastopathy look like on ultrasound?

A commonly described pattern is an irregular hypoechoic lesion with an indistinct margin, sometimes accompanied by posterior acoustic shadowing.

5. Why does diabetic mastopathy cause acoustic shadowing?

Dense fibrosis increases tissue stiffness and acoustic attenuation, which can produce posterior shadowing.

6. Does mammography diagnose diabetic mastopathy?

No. Mammography may demonstrate architectural distortion or asymmetric density, but the findings can overlap with malignancy.

7. Is breast MRI diagnostic?

Not reliably. MRI may help in selected problem-solving situations but can also demonstrate findings that overlap with breast cancer.

8. Is biopsy necessary?

When imaging is suspicious or imaging-pathology uncertainty exists, tissue diagnosis is important. Ultrasound-guided core needle biopsy is particularly useful.

9. Does diabetic mastopathy require surgery?

Not necessarily. Once the diagnosis is securely established and the patient is asymptomatic, conservative surveillance may be appropriate.

10. Can diabetic mastopathy recur?

Yes. Recurrence has been reported, particularly after surgical treatment. A new lesion should nevertheless be evaluated on its own clinical and imaging merits.

29. Take-Home Message

Diabetic mastopathy is rare, but it deserves recognition because it creates one of the most challenging forms of imaging mimicry in breast radiology.

The typical clinical pattern is:

Long-standing diabetes + painless firm breast mass

The imaging pattern may then become:

Dense breast + architectural distortion + irregular hypoechoic lesion ± posterior acoustic shadowing

The problem is that this phenotype overlaps with breast cancer.

Therefore, the correct response is neither automatic reassurance nor automatic surgery.

The appropriate strategy is:

Recognize the possibility → assess the imaging features objectively → assign BI-RADS appropriately → obtain tissue when indicated → establish imaging-pathology concordance → avoid unnecessary surgery when benign disease is securely established.

The most important lesson from this case is:

A diabetic patient with a suspicious breast mass should not be presumed to have cancer—but neither should diabetes be used as a reason to dismiss cancer.

The radiologist's responsibility is to design the safest diagnostic pathway.

30. Conclusion

Diabetic mastopathy is a particularly instructive disease because it exposes the limits of pattern recognition.

The lesion can be hard.

It can be painless.

It can distort the breast architecture.

It can appear irregular and hypoechoic on ultrasound.

And it can look remarkably similar to malignancy.

Yet the underlying biology is different.

Instead of invasive cancer, the tissue demonstrates lymphocytic inflammation and dense fibrosis.

That distinction explains why the disease can produce a pseudotumoral imaging appearance.

For the radiologist, the challenge is therefore not simply to recognize diabetic mastopathy.

The greater skill is knowing when the imaging remains sufficiently suspicious to require biopsy, when pathology is concordant, and when a benign diagnosis can safely prevent unnecessary surgery.

This is also where clinical AI must mature.

An algorithm that identifies an irregular hypoechoic mass may be useful.

An AI system that understands the relationship between diabetes, imaging phenotype, pathology, prior examinations, and clinical context could become considerably more useful.

But even the most sophisticated multimodal system cannot remove the need for clinical judgment and tissue diagnosis when imaging remains suspicious.

Ultimately, diabetic mastopathy teaches a broader lesson that extends well beyond breast imaging:

The goal of medical imaging is not merely to identify abnormalities. It is to understand abnormalities well enough to choose the safest next clinical decision.

Medical Disclaimer

This article is intended for medical education and informational purposes. It does not replace professional medical evaluation, diagnosis, or treatment. Patients with a new or changing breast mass should receive individualized assessment by an appropriately qualified clinician, radiologist, breast surgeon, or other relevant specialist.

References

[1] P. Guzik, T. Gęca, P. Topolewski, et al., “Diabetic Mastopathy: Review of Diagnostic Methods and Therapeutic Options,” International Journal of Environmental Research and Public Health, vol. 19, no. 1, p. 448, 2022, doi: 10.3390/ijerph19010448.

[2] L. Mariano, L. Nicosia, S. Scolari, et al., “Diabetic Mastopathy: A Monocentric Study to Explore This Uncommon Breast Disease,” Diagnostics, vol. 14, no. 23, p. 2749, 2024, doi: 10.3390/diagnostics14232749.

[3] J. Kim, E.-K. Kim, M. J. Kim, H. J. Moon, and J. H. Yoon, “Diabetic mastopathy: imaging features and the role of image-guided biopsy in its diagnosis,” Ultrasonography, vol. 35, no. 2, pp. 140–147, 2016, doi: 10.14366/usg.15052.

[4] K. T. Wong, G. M. K. Tse, and W. T. Yang, “Ultrasound and MR Imaging of Diabetic Mastopathy,” Clinical Radiology, vol. 57, no. 8, pp. 730–735, 2002, doi: 10.1053/crad.2002.0936.

[5] D. Andrews-Tang, A. B. Diamond, L. Rogers, and D. Butler, “Diabetic Mastopathy: Adjunctive Use of Ultrasound and Utility of Core Biopsy in Diagnosis,” The Breast Journal, vol. 6, no. 3, pp. 183–188, 2000, doi: 10.1046/j.1524-4741.2000.99073.x.

[6] J. M. Sabaté, M. Clotet, A. Gómez, et al., “Radiologic evaluation of uncommon inflammatory and reactive breast disorders,” RadioGraphics, vol. 25, no. 2, pp. 411–424, 2005, doi: 10.1148/rg.252045077.

[7] K. Thorncroft, L. Forsyth, S. Desmond, and R. A. Audisio, “The diagnosis and management of diabetic mastopathy,” The Breast Journal, vol. 13, no. 6, pp. 607–613, 2007, doi: 10.1111/j.1524-4741.2007.00489.x.

[8] R. Valdez, J. Thorson, W. G. Finn, et al., “Lymphocytic Mastitis and Diabetic Mastopathy: A Molecular, Immunophenotypic, and Clinicopathologic Evaluation of 11 Cases,” Modern Pathology, vol. 16, no. 3, pp. 223–228, 2003, doi: 10.1097/01.MP.0000056627.21128.74.

[9] K. A. Ely, G. Tse, J. F. Simpson, et al., “Diabetic mastopathy: a clinicopathologic review,” American Journal of Clinical Pathology, vol. 113, no. 4, pp. 541–545, 2000, doi: 10.1309/K5HM-9603-PQ5T-KY3F.

[10] Y. Sakuhara, T. Shinozaki, Y. Hozumi, et al., “MR imaging of diabetic mastopathy,” American Journal of Roentgenology, vol. 179, no. 5, pp. 1201–1203, 2002, doi: 10.2214/ajr.179.5.1791201.

[11] V. Suvannarerg, T. Claimon, P. Sitthinamsuwan, et al., “Clinical, mammographic, and ultrasonographic characteristics of diabetic mastopathy: a case series,” Clinical Imaging, vol. 53, pp. 204–209, 2019, doi: 10.1016/j.clinimag.2018.11.002.

Diabetic Mastopathy: When a Benign Breast Lesion Mimics Cancer